Kannalife Sciences was mentioned in an article by MMJ Business Daily about their new licensing deal with the NIH.
“A pharmaceutical company has inked a licensing agreement with the National Institutes of Health (NIH) to develop, test and possibly sell cannabis-based drugs for use in treating head trauma.”
Under the agreement, Kannalife Sciences will research CBD and other cannabis-derived treatments for chronic traumatic encephalopathy (CTE), a degenerative brain condition most common among athletes who played contact sports.
